Results 91 to 100 of about 519,004 (292)

Somatic variation as an incidental finding in the pediatric next-generation sequencing era [PDF]

, 2021
Marilena Melas, Mariam Mathew, Mari Mori, Vijayakumar Jayaraman, Sarah A. Wilson, Cortlandt Martin, Amanda Jacobson‐Kelly, Ben Kelly, Vincent Magrini, Elaine R. Mardis, Catherine E. Cottrell, Kristy Lee   +11 more
openalex   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Herpes simplex virus associated sepsis in an immunocompetent adult: the value of next-generation sequencing

, 2020
Shan Li, Wei Jiang, Jinmin Peng, Bin Du, Li Weng   +4 more
openalex   +1 more source

GAM-NGS: genomic assemblies merger for next generation sequencing [PDF]

, 2013
Riccardo Vicedomini, Francesco Vezzi, Simone Scalabrin, Lars Arvestad, Alberto Policriti   +4 more
openalex   +1 more source

Next-generation Sequencing and Norovirus [PDF]

Future Virology, 2016
Cotten, Matthew, Koopmans, Marion
openaire   +3 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Editorial: Immunopeptidomic Approaches for the Identification of Tumor (neo)Antigens

Frontiers in Immunology, 2022
Jennie R. Lill, Michal Bassani-Sternberg
doaj   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

, 2020
Mattia D’Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, Even H. Rustad, Elisa Genuardi, Andréa Capra, Stefania Oliva, Daniel Auclair, Jennifer Yesil, Paola Colucci, Jonathan J. Keats, Manuela Gambella, Sara Bringhen, Alessandra Larocca, Mario Boccadoro, Niccolò Bolli, Francesco Maura, Francesca Gay   +17 more
openalex   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source